PE20020322A1 - Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 - Google Patents
Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2Info
- Publication number
- PE20020322A1 PE20020322A1 PE2001000821A PE2001000821A PE20020322A1 PE 20020322 A1 PE20020322 A1 PE 20020322A1 PE 2001000821 A PE2001000821 A PE 2001000821A PE 2001000821 A PE2001000821 A PE 2001000821A PE 20020322 A1 PE20020322 A1 PE 20020322A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- agent
- cyclooxygenase
- methylsulfonil
- phenyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- 238000004090 dissolution Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- 229930195725 Mannitol Natural products 0.000 abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 239000000594 mannitol Substances 0.000 abstract 2
- 235000010355 mannitol Nutrition 0.000 abstract 2
- -1 3-HYDROXY-3-METHYL-1-BUTOXY Chemical class 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003314 deracoxib Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229960004945 etoricoxib Drugs 0.000 abstract 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 239000007935 oral tablet Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960000371 rofecoxib Drugs 0.000 abstract 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 229960002004 valdecoxib Drugs 0.000 abstract 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE UNA COMPOSICION ORAL DE RAPIDA DISOLUCION QUE COMPRENDE a)IMPEDIR LA AGLOMERACION AGREGANDO DE 0,05% A 5% DE UN HUMECTANTE (LAURIL SULFATO DE SODIO) PREVIAMENTE A LA DROGA b)GRANULAR EN HUMEDO i)DE 1% A 75% DE UN INHIBIDOR DE CICLOOXIGENASA 2 DE FORMULA I DONDE R3 ES METILO, AMINO; R4 ES H, ALQUIL, ALCOXI C1-C4; X ES N, CR5; R5 ES H, HALOGENO; Y E Z SON C, N; SIENDO COMPUESTOS PREFERIDOS CELECOXIB, DERACOXIB, VALDECOXIB, ROFECOXIB, ETORICOXIB, 2-(3,5-DIFLUOROFENIL)-3-[4-METILSULFONIL)FENIL]-2-CICLOPENTEN-1-ONA, ACIDO (S)-6,8-DICLORO-2-(TRIFLUOROMETIL)-2H-1-BENZOPIRAN-3-CARBOXILICO; 2-[3,4-DIFLUOROFENIL)-4-(3-HIDROXI-3-METIL-1-BUTOXI)-5-[4-(METILSULFONIL)FENIL]-3-(2H)-PIRIDAZINONA; JUNTO CON ii)UN AGENTE AGLUTINANTE QUE COMPRENDE DE 1% A 10% DE UN SACARIDO DE ALTA MOLDEABILIDAD COMO LACTOSA, MANITOL, GLUCOSA, ENTRE OTROS; O DE 10% A 90% DE UN SACARIDO DE BAJA MOLDEABILIDAD COMO MANITOL DE GRADO EN POLVO SIENDO LA PROPORCION DE 2:100 A 20:100; c)MEZCLAR LOS GRANULOS CON UN LUBRICANTE, UN AGENTE EDULCORANTE, UN AGENTE SABORIZANTE PARA FORMAR UNA MEZCLA EN FORMA DE TABLETA; d)COMPRIMIR LA MEZCLA PARA FORMAR TABLETAS ORALES DE RAPIDA DISOLUCION; e)AGREGAR DE 0,05% A 5% DE UN DESLIZANTE COMO DIOXIDO DE SILICIO; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE EL INHIBIDOR DISPERSADO EN UNA MATRIZ QUE COMPRENDE UN SACARIDO DE BAJA Y ALTA MALDEABILIDAD QUE SE DESINTEGRA EN UNOS 30 A 300 SEGUNDOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22634900P | 2000-08-18 | 2000-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020322A1 true PE20020322A1 (es) | 2002-05-10 |
Family
ID=37515865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000821A PE20020322A1 (es) | 2000-08-18 | 2001-08-17 | Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20020119193A1 (es) |
| AR (1) | AR030382A1 (es) |
| PE (1) | PE20020322A1 (es) |
| TW (1) | TWI256305B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| JP4906233B2 (ja) | 2002-03-01 | 2012-03-28 | ユニバーシティー オブ サウス フロリダ | 少なくとも１種の有効薬剤成分を含有する多構成要素固相 |
| AU2003243699B2 (en) * | 2002-06-21 | 2009-01-15 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| AU2003267231A1 (en) * | 2002-09-20 | 2004-04-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| RS20050390A (sr) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor |
| GB0228465D0 (en) * | 2002-12-06 | 2003-01-08 | Univ Belfast | A method of treating disease |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| AT413944B (de) * | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | Verwendung von oxicam-verbindungen |
| JP2007509154A (ja) * | 2003-10-21 | 2007-04-12 | ファルマシア・コーポレーション | ホスホジエステラーゼ４阻害剤と組み合わせたシクロオキシゲナーゼ−２阻害剤による呼吸器炎症のの治療または予防のための方法およびその組成物 |
| US20050113410A1 (en) * | 2003-11-03 | 2005-05-26 | Mark Tawa | Pharmaceutical salts of zafirlukast |
| AU2005238220A1 (en) * | 2004-04-29 | 2005-11-10 | Binder, Eva | Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives |
| BRPI0512900A (pt) * | 2004-06-30 | 2008-04-15 | Albemarle Corp | composição farmacêutica compreendendo de ibuprofeno, processo de preparação dos gránulos enriquecidos em ibuprofeno e os gránulos secos feitos por este processo |
| EP1808163A1 (en) * | 2005-12-22 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| WO2007073389A1 (en) * | 2005-12-22 | 2007-06-28 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| US20070148245A1 (en) * | 2005-12-22 | 2007-06-28 | Ilan Zalit | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| KR20090051240A (ko) * | 2006-09-01 | 2009-05-21 | 유에스브이 리미티드 | 세벨라머 염산염의 제조방법 및 그의 제형 |
| JP2010539993A (ja) * | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| MX2011007760A (es) * | 2009-01-22 | 2011-08-17 | Usv Ltd | Composiciones farmaceuticas que comprenden polimero vinculante a fosfato. |
| CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN108057025A (zh) * | 2017-12-08 | 2018-05-22 | 佛山市弘泰药物研发有限公司 | 一种依托考昔口崩片及其制备方法 |
| CN111407733A (zh) * | 2020-03-19 | 2020-07-14 | 大桐制药（中国）有限责任公司 | 一种塞莱昔布片剂的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2373931A1 (en) * | 1999-05-17 | 2000-11-23 | Richard Love | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| DK1150959T3 (da) * | 1999-12-08 | 2008-06-02 | Pharmacia Corp | Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed |
-
2001
- 2001-08-17 TW TW090120287A patent/TWI256305B/zh not_active IP Right Cessation
- 2001-08-17 AR ARP010103961A patent/AR030382A1/es unknown
- 2001-08-17 US US09/932,494 patent/US20020119193A1/en not_active Abandoned
- 2001-08-17 PE PE2001000821A patent/PE20020322A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20020119193A1 (en) | 2002-08-29 |
| TWI256305B (en) | 2006-06-11 |
| AR030382A1 (es) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020322A1 (es) | Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 | |
| ES2307041T3 (es) | Tableta que contiene ester etilico del acido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico o sus sales. | |
| RU2319701C2 (ru) | ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I | |
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| UA84318C2 (ru) | Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе | |
| KR960041166A (ko) | 4-(아릴아미노 메틸렌)-2,4-디하이드로-3-피라졸론 | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| PE20020799A1 (es) | Una composicion farmaceutica con tendencia reducida a la cristalizacion del farmaco | |
| TNSN02021A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
| TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| TR200001530T2 (tr) | Gastrik asit salgılamasının önlenmesi için heterosiklik bileşimler | |
| AR066780A1 (es) | Formulaciones que contienen triazinonas y hierro | |
| YU2803A (sh) | 4-fenil-piridin derivati kao antagonisti neurokinin-1 receptora | |
| CA2624621A1 (en) | Pyrazine derivatives | |
| SE9903831D0 (sv) | Formulation of substituted benzimidazoles | |
| PE20040084A1 (es) | Combinaciones de medicamentos que contienen compuestos heterociclicos y un nuevo agente anticolinergico | |
| SE0201194D0 (sv) | New compounds | |
| PE20010254A1 (es) | Pesticidas a base de derivados de indazol o benzotriazol | |
| NO304227B1 (no) | Substituerte imidazolderivater, preparat som inneholder disse og deres anvendelse | |
| CY1111578T1 (el) | Σουλφαμιδες ως antαγωνιστες του υποδοχεα ενδοθηλινης για τη θεραπεια καρδιαγγειακων νοσων | |
| ATE440838T1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| PE20061155A1 (es) | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas | |
| MY125394A (en) | Novel compounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |